AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Canine Erythropoietin Gene and Recombinant Protein

Detailed Technology Description
Anemia, a condition in which too few red blood cells (RBCs) are in circulation is characterized by clinical signs of weakness, lethargy and inappetance and can be divided into two forms - regenerative and nonregenerative
Others
MacLeod JN et al. Expression and bioactivity of recombinant canine erythropoietin. Am J Vet Res. 1998 Sep;59(9):1144-8.

http://www.ncbi.nlm.nih.gov/pubmed/9736393?ordinalpos=18&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Randolph JE et al. Clinical efficacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia. J Vet Intern Med. 2004 Jan-Feb;18(1):81-91.

http://www.ncbi.nlm.nih.gov/pubmed/14765736?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Randolph JF et al. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs. Am J Vet Res. 1999 May;60(5):636-42.

http://www.ncbi.nlm.nih.gov/pubmed/10328437?ordinalpos=17&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
*Abstract

Anemia, a condition in which too few red blood cells (RBCs) are in circulation is characterized by clinical signs of weakness, lethargy and inappetance and can be divided into two forms - regenerative and nonregenerative. In regenerative anemia, the bone marrow continuously produces RBCs in response to blood loss (eg, during surgery or trauma) or destruction of RBCs by the immune system. In nonregenerative anemia, the bone marrow cannot or does not respond to the anemia. Its potential causes include, among other chronic diseases, chronic renal failure (CRF) and cancer.

Human erythropioietin (hEPO), a glycosylated protein that stimulates RBC production is commercially available to treat nonregenerative anemia caused by CRF and cancer, with global annual sales exceeding $10 billion dollars. However, CRF and other chronic diseases that cause milder forms of nonregenerative anemia are also significant problems in canines.

Without commercially available canine EPO (cEPO), veterinarians must weigh potential benefit of hEPO treatment against serious potential risk in canines - the development of neutralizing antibodies, which render therapy ineffective and potentially cross-neutralize endogenous EPO, which can cause a life threatening condition called red cell aplasia.

The current invention has identified the cEPO gene and describes the increased safety and efficacy of recombinant cEPO in the treatment of nonregenerative anemia in dogs.

Advantages
  • Increased safety and efficacy in the treatment of nonregenerative anemia in canines
  • High recombinant cEPO protein expression system in Chinese Hamster Ovary (CHO) cells

    See also D-2778: Feline Erythropoietin Expression System

    •
    *Licensing
    Phillip Owh, Senior Technology Commercialization and Liaison Officerpo62@cornell.edu607-254-4508
    Country/Region
    USA

    For more information, please click Here
    Mobile Device